Rosacea-like facial rash related to metformin administration in a young woman

Mumoli, Laura; Gambardella, Antonio; Labate, Angelo; Succurro, Elena; Sarro, Giovambattista De; Arturi, Franco; Gallelli, Luca

doi:10.1186/2050-6511-15-3

Cited by 17 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with our previous paper [24][25][26], using the Naranjo score, we documented a probable association between adefovir and clinical symptoms.…”

Section: Key Pointssupporting

confidence: 93%

Adefovir dipivoxil-induced development of osteomalacia and Fanconi syndrome during the treatment of hepatitis B virus (HBV)-related cirrhosis

Staltari¹,

Caroleo

Michniewicz

et al. 2014

CMI

Self Cite

View full text Add to dashboard Cite

A 55-year-old man (height = 175 cm, weight = 68 kg, Body Mass Index = 22.2 kg/ m 2 ) came to our observation in December 2012 due to the onset of bone pain, muscle cramps, and asthenia. Past history revealed that about 24 years before (1988) a chronic hepatitis B (anti-HBe positive) infection was diagnosed and 15 years later (2003) liver biopsy and endoscopy documented the presence of cirrhosis (Child 5A) with esophageal varices, respectively.On 2005, a treatment with pegylated interferon (180 µg/week subcutaneously) was started (HBV-DNA = 10,000,000 IU/ml), but 18 months later (February 2007) for the persistence of high HBV-DNA levels (HBV-DNA = 352,000 IU/ml), pegylat- Why we describe this caseNotwithstanding adefovir is considered safe at the dosage of 10 mg/day, renal function must be carefully evaluated in order to prevent systemic disease and bone fracture. This case report could be useful in order to perform an appropriate prescription in HBV patients treated with adefovir and a risk of kidney or bone disease (e.g. patients taking non steroidal antinflammatory drugs, aminoglycosides, corticosteroids or menopausal women) ed-interferon was stopped and lamivudine (100 mg/day) was administered. During the follow-up, three months later ( Rate before adefovir = 78.26 ml/min/1.73 m 2 ; during adefovir treatment = 57.38 ml/min/1.73 m 2 ) Abstract Adefovir dipivoxil is a nucleotide analog reverse transcriptase inhibitor used to treat adult patients affected by HBeAg-positive and HBeAg-negative chronic hepatitis B and with clinical evidence of lamivudine-resistant hepatitis B virus (HBV). Adefovir administered at a dosage of 10 mg/day is generally well tolerated, even if renal toxicity, type Fanconi syndrome, was reported during long-term treatments. We report a case of osteomalacia with Fanconi syndrome and pathologic fracture of the femur related to long-time (67 months) adefovir treatment (10 mg/day) in a patient with compensated hepatitis B virus (HBV) cirrhosis (Child 5A) and with a previous normal renal function (estimated Glomerular Filtration . The patient was switched to entecavir at a dose of 1 mg/day, with both suppression of viremia and improvement of osteomalacia and Fanconi syndrome; the patient's follow-up is still ongoing after 22 months. Sviluppo di osteomalacia e di sindrome di Fanconi durante il trattamento con adefovir in un paziente affetto da cirrosi epatica HBV-correlataCMI 2014; 8(4): 109-114 http://dx.doi.org/10.7175/cmi.v8i4.969 1 Rete Regionale di informazione sul farmaco,

show abstract

“…In agreement with our previous paper [24][25][26], using the Naranjo score, we documented a probable association between adefovir and clinical symptoms.…”

Section: Key Pointssupporting

confidence: 93%

Adefovir dipivoxil-induced development of osteomalacia and Fanconi syndrome during the treatment of hepatitis B virus (HBV)-related cirrhosis

Staltari¹,

Caroleo

Michniewicz

et al. 2014

CMI

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previously, several authors reported that many factors (e.g. drugs, allergy, bit of animals, parasites) are able to induce skin manifestations [10][11][12][13][14]. In our cases, clinical history suggested that probably Panitumumab could play a role in these skin manifestations.…”

Section: Discussionsupporting

confidence: 51%

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Ciliberto

Ierardi

Caroleo

et al. 2019

CDS

Self Cite

View full text Add to dashboard Cite

Background: Panitumumab is an EGFR inhibitor used for the treatment of metastatic colorectal cancer (mCRC), even if its use is related to skin toxicity. Case Presentation: We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5- fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC. Results: In both patients, clinical, laboratory and radiological evaluation documented the presence of a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation and antimicrobial + corticosteroid treatment induced a remission of skin manifestations. Conclusion: We reported for the first time the development of panniculitis during Panitumumab treatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or oxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with mCRC, without the development of adverse drug reactions or drug-drug interactions.

show abstract

“…It is commonly associated with gastrointestinal adverse effects, yet dermatologic reactions to metformin are uncommon and the literature detailing these events and their management is sparse [ 2 ]. Case reports of possible reactions to metformin include erythema multiforme, lichen planus, rosacea, and pseudoporphyria [ 3 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

Metformin-Induced Fixed-Drug Eruption Confirmed by Multiple Exposures

2016

View full text Add to dashboard Cite

Patient: Female, 56Final Diagnosis: Fixed-drug eruptionSymptoms: —Medication: MetforminClinical Procedure: Discontinued metforminSpecialty: Family MedicineObjective:Unusual or unexpected effect of treatmentBackground:A fixed-drug eruption (FDE) is a reaction characterized by cutaneous lesions that appear due to exposure to a particular drug. Barbiturates, carbamazepine, sulfamethoxazole, and tetracyclines have all been associated with causation of FDEs. Although these drugs are more commonly associated with FDEs, any introduction of a medication has the potential to result in a FDE. Metformin, a commonly used medication to improve glycemic control, has been reported to cause dermatologic reactions in some case reports, but only a single previously documented case report discusses the potential of metformin-associated FDE.Case Report:We describe a 56-year-old woman who developed a FDE with multiple exposures to metformin. Upon each exposure, small, round, erythematic lesions developed on the palms of the hands and soles of the feet; these lesions resolved each time after discontinuation of metformin. According to the Naranjo scale, there is a definite association between metformin and FDE in this case (score of 8).Conclusions:This report contributes to the limited documented literature on metformin-induced FDE. Clinicians should be made aware of possible FDEs associated with this commonly used medication.

show abstract

Rosacea-like facial rash related to metformin administration in a young woman

Cited by 17 publications

References 14 publications

Adefovir dipivoxil-induced development of osteomalacia and Fanconi syndrome during the treatment of hepatitis B virus (HBV)-related cirrhosis

Adefovir dipivoxil-induced development of osteomalacia and Fanconi syndrome during the treatment of hepatitis B virus (HBV)-related cirrhosis

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Metformin-Induced Fixed-Drug Eruption Confirmed by Multiple Exposures

Contact Info

Product

Resources

About